Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92629 | 0.81 | FUCA1 (0.30) | FUCA1 | |
| Hydrochloric Acid SCHEMBL34473882 | 0.79 | — | — | |
| SCHEMBL2928744 | 0.78 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL24812981 | 0.78 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL2928741 | 0.78 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL2948327 | 0.77 | ALOX15 (0.35) | ALOX15 | |
| SCHEMBL18580080 | 0.76 | GBA1 (0.37) | FUCA1 | |
| SCHEMBL11608191 | 0.76 | GBA1 (0.37) | FUCA1 | |
| SCHEMBL22113128 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL6956702 | 0.74 | GBA1 (0.35) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569632-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2023-12-06 | — | — | EP | claimed |
| EP-3569631-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-3569632-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | claimed |
| EP-3569631-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | claimed |
| EP-3569632-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3569631-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3569631-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569632-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | ALOX15 491/4885FUCA1 3623/4885 |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | ALOX15 3795/4885FUCA1 3632/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | ALOX15 4539/4885FUCA1 4525/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | ALOX15 3795/4885FUCA1 3632/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | ALOX15 4332/4885FUCA1 4602/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | ALOX15 3795/4885FUCA1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.